Literature DB >> 8383511

Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects.

E Reihsaus1, M Innis, N MacIntyre, S B Liggett.   

Abstract

It has long been hypothesized that a defective beta 2-adrenergic receptor (beta 2AR) may be a pathogenic factor in bronchial asthma. We examined the gene encoding the beta 2AR to assess the frequency of polymorphisms in 51 patients with moderate to severe asthma and 56 normal subjects. Nine different point mutations were found in both heterozygous and homozygous forms at nucleic acid residues 46, 79, 100, 252, 491, 523, 1053, 1098, and 1239. No mutations resulting in large deletions or frame shifts were detected. Of these nine polymorphisms, four were found to cause changes in the encoded amino acids at residues 16, 27, 34, and 164. The most frequent polymorphisms were arginine 16 to glycine (Arg16-->Gly) and glutamine 27 to glutamic acid (Gln27-->Glu). The other two polymorphisms, valine 34 to methionine, and threonine 164 to isoleucine, occurred in only four subjects. The incidence of beta 2AR homozygous polymorphisms was no greater in asthmatic patients as compared with controls (Arg16-->Gly: 53% versus 59%, Gln27-->Glu: 24% versus 29%, respectively; P = NS). Some subjects were found to have both of these polymorphisms simultaneously, but there was no difference in incidence between the two groups, with 23% of asthmatics and 28% of normal subjects being homozygous for both polymorphisms. The apparently normal subjects with both polymorphisms did not have subclinical hyperreactive airways disease as determined by methacholine challenge testing. In the asthma group, one mutation (Arg16-->Gly) identified a subset of patients with a distinct clinical profile.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383511     DOI: 10.1165/ajrcmb/8.3.334

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  120 in total

1.  Mutation screening of the muscarinic M(2) and M(3) receptor genes in normal and asthmatic subjects.

Authors:  A G Fenech; M J Ebejer; A E Felice; R Ellul-Micallef; I P Hall
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 2.  Th1/Th2 balance in atopy.

Authors:  T Biedermann; M Röcken
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

4.  Identification of novel polymorphisms within the promoter region of the human beta2 adrenergic receptor gene.

Authors:  M G Scott; C Swan; A P Wheatley; I P Hall
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

5.  Genotyping and drug response: use of single nucleotide polymorphisms (SNPs) versus haplotypes to predict albuterol efficacy.

Authors:  S Schubbert
Journal:  AAPS PharmSci       Date:  2001

6.  High-throughput genotyping with single nucleotide polymorphisms.

Authors:  K Ranade; M S Chang; C T Ting; D Pei; C F Hsiao; M Olivier; R Pesich; J Hebert; Y D Chen; V J Dzau; D Curb; R Olshen; N Risch; D R Cox; D Botstein
Journal:  Genome Res       Date:  2001-07       Impact factor: 9.043

Review 7.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

8.  Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms.

Authors:  Tianhua Niu; Zhaohui S Qin; Xiping Xu; Jun S Liu
Journal:  Am J Hum Genet       Date:  2001-11-26       Impact factor: 11.025

Review 9.  Pharmacogenetics of asthma.

Authors:  A Fenech; Ian P Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 10.  Genetic polymorphisms of adrenergic receptors.

Authors:  E M Garland; I Biaggioni
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.